SCVC

Science Creates Ventures is a Bristol-based venture capital firm that specializes in early-stage deep tech investments. The firm focuses on technologies capable of enhancing healthcare, improving quality of life, and addressing environmental challenges. It is part of a broader deep tech ecosystem supported by experienced entrepreneurs, which aims to help scientists and engineers turn their scientific discoveries into successful businesses. In collaboration with the University of Bristol, Science Creates Ventures seeks to position Bristol as a leading global hub for deep tech innovation by offering specialized incubator facilities and a network of strategic partners.

Laura Davies

Investment Manager

Catherine Fletcher

Principal

6 past transactions

Forefront RF

Venture Round in 2023
Forefront RF is a fabless semiconductor company.

Nebu-Flow

Seed Round in 2022
Nebu-Flow is focused on developing advanced nebulizers aimed at improving the delivery of treatments for patients with respiratory disorders. The company has created a novel pulmonary drug-delivery technology that facilitates the efficient administration of difficult-to-nebulize medications directly to the lungs. This includes both existing formulations and innovative therapeutics such as biologics, nanomedicines, and vaccines. By enhancing the delivery of these treatments, Nebu-Flow aims to support medical professionals in addressing and curing various respiratory diseases.

OxDX

Pre Seed Round in 2022
OxDX is a spinout that combines the power of single-molecule fluorescent microscopy with machine learning to identify pathogens in under a minute. They use a universal labelling system to light up everything in our sample, image the sample using super-resolution fluorescence microscopy, and analyse the images in our neural network.

Imophoron

Seed Round in 2021
Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).

Forefront RF

Seed Round in 2021
Forefront RF is a fabless semiconductor company.

Cytoseek

Seed Round in 2021
Cytoseek Limited, founded in 2017 and based in Bristol, United Kingdom, specializes in developing innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. As a spinout from the University of Bristol, the company utilizes a unique cell membrane augmentation technology that enhances cell therapies by adding new functionalities, such as tissue-specific targeting and improved cell survivability. Currently, Cytoseek is conducting proof of principle studies to validate the effectiveness of its therapies and is actively seeking partnerships with other cell therapy companies to advance these treatments into clinical settings, ultimately aiming to improve human health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.